Financial Performance - Net loss for the three months ended September 30, 2024, was $2.0 million, compared to $6.0 million for the same period in 2023[8]. - The company reported a basic and diluted net loss per share of $0.18 for the three months ended September 30, 2024, compared to $0.48 for the same period in 2023[12]. Cash and Liquidity - As of September 30, 2024, cash equivalents totaled $3.0 million, down from $3.4 million as of December 31, 2023[3]. - Net cash used in operating activities was $6.6 million for the nine months ended September 30, 2024, compared to $12.2 million for the same period in 2023[3]. - The company is exploring opportunities for additional funding to meet Nasdaq's minimum stockholders' equity requirement by December 24, 2024[3]. Expenses - Research and development (R&D) expenses were $1.0 million for the three months ended September 30, 2024, compared to $5.2 million for the same period in 2023, reflecting a significant reduction[5]. - Total operating expenses for the three months ended September 30, 2024, were $2.2 million, down from $6.9 million for the same period in 2023[12]. - General and administrative expenses for the three months ended September 30, 2024, were $1.2 million, down from $1.6 million for the same period in 2023[6]. Revenue - Collaboration and research and development revenue for the three months ended September 30, 2024, was $10,000, compared to $16,000 for the same period in 2023[12]. Liabilities - As of September 30, 2024, total liabilities were $6.4 million, compared to $8.2 million as of December 31, 2023[13].

Technical Analysis - A hammer chart pattern has formed in Cyclacel Pharmaceuticals' last trading session, indicating a potential trend reversal as bulls counteract bears to find support [1] - The hammer pattern is a technical indication of nearing a bottom with likely subsiding of selling pressure, signaling that bears might have lost control over the price [1][2] - Hammer candles can occur on any timeframe and are utilized by both short-term and long-term investors, but should be used in conjunction with other bullish indicators [2] Fundamental Analysis - Wall Street analysts have shown strong agreement in raising earnings estimates for Cyclacel Pharmaceuticals, enhancing its prospects of a trend reversal [1] - The consensus EPS estimate for the current year has increased by 53.6% over the last 30 days, indicating that analysts expect better earnings than previously predicted [3] - Cyclacel Pharmaceuticals currently has a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 stocks ranked based on earnings estimate revisions and EPS surprises [3] Market Performance - Cyclacel Pharmaceuticals' stock has lost 13.8% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal [1] - Stocks with a Zacks Rank 1 or 2, like Cyclacel Pharmaceuticals, usually outperform the market, further supporting the likelihood of a trend reversal [3]

Financial Data and Key Metrics Changes - As of June 30, 2024, cash equivalents totaled $6 million, an increase from $3.4 million as of December 31, 2023 [9] - Net cash used in operating activities was $3.6 million for the six months ended June 30, 2024, compared to $8.2 million for the same period in 2023 [9] - Net loss for the three months ended June 30, 2024, was $3.3 million, down from $5.5 million for the same period in 2023 [10] Business Line Data and Key Metrics Changes - Research and development (R&D) expenses were $2 million for the three months ended June 30, 2024, compared to $4.7 million for the same period in 2023 [9] - R&D expenses related to Fadra were $1.5 million for the three months ended June 30, 2024, down from $3 million for the same period in 2023 [9] - R&D expenses for plogosertib were $0.5 million for the three months ended June 30, 2024, compared to $1.4 million for the same period in 2023 [9] Market Data and Key Metrics Changes - The company is focusing on a precision medicine strategy for Fadra, an oral CDK29 inhibitor, with recruitment in the enriched cohort of the Phase 2 proof-of-concept study progressing well [3][5] - Initial clinical activity from the Phase 2 proof-of-concept study is expected to be reported starting in the fourth quarter of 2024 [5] Company Strategy and Development Direction - The company aims to address unmet medical needs in patients with CDKN2A and/or CDKN2B chromosomal abnormalities through its Fadra program [3][5] - The competitive profile of Fadra is considered strong within its therapeutic class, with expectations for significant clinical data in the near future [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recruitment pace in the Fadra study and anticipates reporting initial results from around a dozen patients by the end of 2024 [6][13] - The company is focused on evaluating specific cancer types in the Phase 2 proof-of-concept study based on preliminary data [8] Other Important Information - The United Kingdom research and development tax credits for the three months ended June 30, 2024, were $0.4 million, down from $6 million for the same period in the previous year [10] - The company estimates that its current cash resources will fund planned programs into the fourth quarter of 2024 [9] Q&A Session Summary Question: What is the enrollment target for the CDKN2A and 2B program? - The target is approximately 12 to 14 patients, with a need to see more than two responses to move to the next phase of the study [11][12] Question: How many patients are you planning to show data in the second half of this year? - The company anticipates presenting response data from around a dozen patients by the end of the year [13] Question: Is there any reason to change the local CDKN2B, 2A and 2B to a more potent form instead of the mutations and other alterations? - The company will analyze various alterations and mutations to determine their impact on drug efficacy [14]

Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $6.60 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.25%. A quarter ago, it was expected that this company would post a loss of $4.93 per share when it actually produced a loss of $2.27, delivering a surprise of 53.96%. Over the last four quarters, the com ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CYCC The Nasdaq Stock Market LLC Preferred Stock, $0.001 par value CYCCP The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...

Financial Position - As of June 30, 2024, cash equivalents totaled $6.0 million, an increase from $3.4 million as of December 31, 2023[3]. - The company estimates that its current cash resources will fund planned programs into the fourth quarter of 2024[3]. - Total liabilities decreased to $7.191 million as of June 30, 2024, from $8.198 million as of December 31, 2023[11]. Operating Activities - Net cash used in operating activities was $3.6 million for the six months ended June 30, 2024, compared to $8.2 million for the same period in 2023[3]. Research and Development - Research and development (R&D) expenses were $2.0 million for the three months ended June 30, 2024, down from $4.7 million for the same period in 2023[4]. - Fadraciclib R&D expenses were $1.5 million for the three months ended June 30, 2024, compared to $3.0 million for the same period in 2023[4]. - The company is nearing completion of recruitment in the precision medicine cohort for the 065-101 study[2]. - The company anticipates reporting interim data from the 065-101 Phase 2 study in the fourth quarter of 2024[2]. Net Loss - Net loss for the three months ended June 30, 2024, was $3.3 million, compared to $5.5 million for the same period in 2023[5]. General and Administrative Expenses - General and administrative expenses remained flat at approximately $1.6 million for each of the three months ended June 30, 2024, and 2023[4].

BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2024 financial results on Wednesday, August 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call: (2 ...

Cyclacel Pharmaceuticals, Inc. (CYCC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. ...

Investors might want to bet on Cyclacel Pharmaceuticals, Inc. (CYCC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ye ...

The data showed that CRC PDOs were more sensitive to fadraciclib treatment than either chemotherapy or palbociclib. The investigators demonstrated fadraciclib's ability to inhibit both CDK2 and CDK9, cause anaphase catastrophe, downregulate MYC protein levels and induce apoptosis. These findings translated to significant tumor growth inhibition by fadraciclib in matched CRC PDX models. The study concluded that fadraciclib has potential as a therapy for advanced CRC and that CDK2/9 inhibition impacts multipl ...